ACC 2021 | HOST-EXAM: Clopidogrel vs ASA monotherapy post DAPT in PCI patients

Clopidogrel monotherapy after dual antiplatelet therapy (DAPT) was associated with reduced mortality, MI, stroke, and other events in patients receiving PCI compared against aspirin monotherapy (ASA).

ACC 2021 | HOST-EXAM: Clopidogrel vs AAS como monoterapia post DAPT en las angioplastias

This information was provided by the Korean HOST-EXAM study, presented at ACC 2021 scientific sessions, and simultaneously published in the Lancet.

Researchers followed patients for 2 years and observed consistent results across subgroups, regardless baseline and angiographic characteristics. 

Primary end point, a combination of all cause death, MI, stroke, BARC 3 bleeding or higher, at 24 months, occurred in 5.7% of patients randomized to clopidogrel vs 7.7% of patients randomized to ASA (HR 0.73; IC 95% 0.59 a 0.90).

According to authors, the benefits of clopidogrel were observed both in thrombotic and bleeding terms. However, a longer followup in other populations is necessary (the whole cohort was Korean) to be able to reach more definitive conclusions. 

Guidelines on both sides of the Atlantic recommend ASA at long term after coronary PCI, but these study outcomes challenge ASA.


Read also: ACC 2021 | RAPID-TnT: Usefulness of High-Sensitivity Ultra-Fast Troponin T.


The HOST-EXAM randomized 5530 patients from 37 centers in Korea. All patients were free of events (thrombotic or bleeding) were within 6 to 18 months after coronary PCI and had completed the indicated DAPT period.

At the moment of intervention, over half of patients presented stable angina, 19.4% non-STEMI and 17.2% STEMI.

These new and provocative data raise our expectations for longer followup and similar results across different populations. 

HOST-EXAM

Original Title: Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.

Reference: Bon-Kwon Koo et al. Presentado en el congreso de la ACC 2021 y publicado simultáneamente en Lancet. https://doi.org/10.1016/S0140-6736(21)01063-1.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...